BioSpace News Archive

SK Life Science, Inc. will present data from ten abstracts, including analyses on drug load and the rate of SUDEP in adults with partial-onset (focal) seizures taking XCOPRI® (cenobamate tablets) CV at the American Epilepsy Society (AES) Annual Meeting, to be held in-person in Nashville, TN, December 2–6, 2022.

Bionomics Limited today announced it will present data on the development of an oral tablet formulation of BNC210 for the treatment of Social Anxiety Disorder (SAD) and data on the pharmacometrics analysis and drug reformulation of BNC210 for the treatment of PTSD at the 61st Annual meeting of the American College of Neuropsychopharmacology (ACNP) to be held in-person Sunday through Wednesday, December 4-7, 2022 in Phoenix, Arizona.

Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, announced the company will present two posters at the 2022 San Antonio Breast Cancer Symposium taking place December 6 - 10, 2022 in San Antonio, Texas.

PainTEQ, a fast-growing medical innovation company and the creator of LinQ, a minimally invasive therapy for SI joint (SIJ) dysfunction, announced the appointment of Michael Mydra as its new Senior Vice President.

NRx Pharmaceuticals, Inc. today announced it received written notice on December 1, 2022 from The Nasdaq Stock Market informing NRx Pharmaceuticals that it has regained compliance with the minimum bid price requirement under the Nasdaq Listing Rule 5450(a)(1).

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase II clinical study of VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist, in the treatment of acute performance anxiety in social situations, such as public speaking.

Oyster Point Pharma, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common stock to three new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.

Lantern Pharma Inc, a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announces that Panna Sharma, CEO and President, will present at the RHK Capital Disruptive Growth Conference in New York City.

Genprex, Inc. today announced that its Executive Vice President will be providing an overview of the Company’s gene therapies for cancer and diabetes at the following investor conference in December 2022.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2022).